Resilia is their anti calcification treatment tissue in their latest TAVR device. But remember that calcification is but one of our competitive advantages. Adapt will be better than Resilia is this area anyway.
The EOA’s won’t change or improve because of a treatment. The Sapien TAVR valve is still made of 3 seperate pieces of tissue and through that design will not be able to get the EOA’s of a normal valve like DurAVR can. The mean gradients is also higher than DurAVR. The coaptation will not work as well effecting the wear and tear of their valve and it’s durability. Not to mention the Commissural alignment of DurAVR.
So as you can see Resilia may come a bit closer to Adapt in terms of calcification resistance but does not have all the benefits of the DurAVR TAVR device that stem from its single piece valve design and resulting innovation in the frame and delivery system.
Plus the Sapien valve has a larger French size than ours which is more invasive as it goes in the femoral artery. I could go on and on and on.
DurAVR is far superior no matter which way you look at it.
DYOR and Not advice
Ann: Anti-Calcification Study, page-42
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |